Fatty liver diseases, bile acids, and FXR
The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide has increased at an alarming rate, which will likely result in enormous medical and economic burden. NAFLD presents as a spectrum of liver diseases ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrh...
Saved in:
Main Authors: | Yan Zhu (Author), Hongxia Liu (Author), Min Zhang (Author), Grace L. Guo (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2016-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bile acid nuclear receptor FXR and digestive system diseases
by: Lili Ding, et al.
Published: (2015) -
Bile Acids, FXR, and Metabolic Effects of Bariatric Surgery
by: Olivier F. Noel, et al.
Published: (2016) -
The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
by: Zhang DY, et al.
Published: (2019) -
Suppressing FXR promotes antiviral effects of bile acids via enhancing the interferon transcription
by: Xue Liang, et al.
Published: (2024) -
Lactobacillus rhamnosus GG ameliorates triptolide-induced liver injury through modulation of the bile acid-FXR axis
by: Shiping Hu, et al.
Published: (2024)